Lupin has successfully completed a PAI inspection (Prior Approval Inspection) carried out by the United States Food and Drug Administration (USFDA) at its Aurangabad manufacturing facility with one 483 observation. The observation was procedural in nature and corrected during the inspection itself.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.